Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
Top Cited Papers
- 20 July 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (21), 2601-2608
- https://doi.org/10.1200/jco.2011.37.2482
Abstract
To investigate whether hormonal receptors and human epidermal growth factor receptor 2 (HER2) change throughout tumor progression, because this may alter patient management. The study cohort included female patients with breast cancer in the Stockholm health care region who relapsed from January 1, 1997, to December 31, 2007. Either biochemical or immunohistochemical (IHC)/immunocytochemical (ICC) methods were used to determine estrogen receptor (ER), progesterone receptor (PR), and HER2 status, which was then confirmed by fluorescent in situ hybridization for IHC/ICC 2+ and 3+ status. ER (459 patients), PR (430 patients), and HER2 (104 patients) from both primary tumor and relapse were assessed, revealing a change in 32.4% (McNemar's test P < .001), 40.7% (P < .001), and 14.5% (P = .44) of patients, respectively. Assessment of ER (119 patients), PR (116 patients), and HER2 (32 patients) with multiple (from two to six) consecutive relapses showed an alteration in 33.6%, 32.0%, and 15.7% of patients, respectively. A statistically significant differential overall survival related to intraindividual ER and PR status in primary tumor and relapse (log-rank P < .001) was noted. In addition, women with ER-positive primary tumors that changed to ER-negative tumors had a significant 48% increased risk of death (hazard ratio, 1.48; 95% CI, 1.08 to 2.05) compared with women with stable ER-positive tumors. Patients with breast cancer experience altered hormone receptor and HER2 status throughout tumor progression, possibly influenced by adjuvant therapies, which significantly influences survival. Hence, marker investigations at relapse may potentially improve patient management and survival.This publication has 30 references indexed in Scilit:
- Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsThe Lancet, 2011
- Should liver metastases of breast cancer be biopsied to improve treatment choice?Annals of Oncology, 2011
- Hormone Receptor and c-ERBB2 Status in Distant Metastatic and Locally Recurrent Breast CancerAmerican Journal of Clinical Pathology, 2010
- Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancerAnnals of Oncology, 2009
- Discordance between Receptor Status in Primary and Metastatic Breast Cancer: an Exploratory Study of Bone and Bone Marrow BiopsiesClinical Oncology, 2008
- Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient ManagementThe Oncologist, 2008
- Effect of Screening and Adjuvant Therapy on Mortality from Breast CancerThe New England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Impact of metastatic estrogen receptor and progesterone receptor status on survivalBreast Cancer Research and Treatment, 2005
- Immunohistochemical Detection of Estrogen Receptors in Paraffin Sections from Primary and Metastatic Breast CancerPathology - Research and Practice, 1989